Reviewed by Michael Gill, B. Sc.
9 Nonalcoholic Fatty Liver Disease Clinical Trials Near Me
Top Hospitals for Nonalcoholic Fatty Liver Disease Clinical Trials
Image of Texas Liver Institute in Texas.
Texas Liver Institute
San Antonio
2Active Trials
7All Time Trials for Nonalcoholic Fatty Liver Disease
2015First Nonalcoholic Fatty Liver Disease Trial
Image of Orange County Research Center in California.
Orange County Research Center
Tustin
2Active Trials
6All Time Trials for Nonalcoholic Fatty Liver Disease
2015First Nonalcoholic Fatty Liver Disease Trial
Top Cities for Nonalcoholic Fatty Liver Disease Clinical Trials
Image of San Antonio in Texas.
San Antonio
6Active Trials
Texas Liver InstituteTop Active Site
Image of Rialto in California.
Rialto
2Active Trials
Inland Empire Clinical Trials, LLCTop Active Site
Nonalcoholic Fatty Liver Disease Clinical Trials by Phase of Trial
Phase 1 Nonalcoholic Fatty Liver Disease Clinical Trials
3Active Nonalcoholic Fatty Liver Disease Clinical Trials
3Number of Unique Treatments
18Number of Active Locations
Nonalcoholic Fatty Liver Disease Clinical Trials by Age Group
18+ Nonalcoholic Fatty Liver Disease Clinical Trials
8Active Nonalcoholic Fatty Liver Disease Clinical Trials
Most Recent Nonalcoholic Fatty Liver Disease Clinical Trials
Top Treatments for Nonalcoholic Fatty Liver Disease Clinical Trials
Treatment Name
Active Nonalcoholic Fatty Liver Disease Clinical Trials
All Time Trials for Nonalcoholic Fatty Liver Disease
First Recorded Nonalcoholic Fatty Liver Disease Trial
Intervention/ Drug
1
1
2022
Dietary intervention
1
2
2015
LY3849891
1
1
2022
AMG 609
1
1
2021
Aspirin 81 mg
1
1
2019
Recently Completed Studies with FDA Approved Treatments for Nonalcoholic Fatty Liver Disease
Treatment
Year
Sponsor
BIO89-100
2021
89bio, Inc.
Efinopegdutide 20 mg/mL
2021
Merck Sharp & Dohme Corp.
TERN-201
2021
Terns, Inc.
ORMD-0801 (Insulin) capsule 8 mg BD
2020
Oramed, Ltd.
PF-06865571
2020
Pfizer

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 16th, 2021

Last Reviewed: November 27th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403. https://pubmed.ncbi.nlm.nih.gov/118325272 Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006 Nov 30;355(22):2297-307. https://pubmed.ncbi.nlm.nih.gov/171355843 Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006 Nov 30;355(22):2297-307. doi: 10.1056/NEJMoa060326. https://pubmed.ncbi.nlm.nih.gov/171355844 Yoshino J, Patterson BW, Klein S. Adipose Tissue CTGF Expression is Associated with Adiposity and Insulin Resistance in Humans. Obesity (Silver Spring). 2019 Jun;27(6):957-962. doi: 10.1002/oby.22463. Epub 2019 Apr 19. https://pubmed.ncbi.nlm.nih.gov/310044095 Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, Tio F, Hardies J, Darland C, Musi N, Webb A, Portillo-Sanchez P. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016 Sep 6;165(5):305-15. doi: 10.7326/M15-1774. Epub 2016 Jun 21. https://pubmed.ncbi.nlm.nih.gov/273227986 Qiu C, Zhang C, Gelaye B, Enquobahrie DA, Frederick IO, Williams MA. Gestational diabetes mellitus in relation to maternal dietary heme iron and nonheme iron intake. Diabetes Care. 2011 Jul;34(7):1564-9. doi: 10.2337/dc11-0135. https://pubmed.ncbi.nlm.nih.gov/217092957 Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care. 1999 Dec;22(12):1978-83. doi: 10.2337/diacare.22.12.1978. https://pubmed.ncbi.nlm.nih.gov/105878298 Cooksey RC, Jones D, Gabrielsen S, Huang J, Simcox JA, Luo B, Soesanto Y, Rienhoff H, Abel ED, McClain DA. Dietary iron restriction or iron chelation protects from diabetes and loss of beta-cell function in the obese (ob/ob lep-/-) mouse. Am J Physiol Endocrinol Metab. 2010 Jun;298(6):E1236-43. doi: 10.1152/ajpendo.00022.2010. Epub 2010 Mar 30. https://pubmed.ncbi.nlm.nih.gov/203541579 Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care. 1999 Dec;22(12):1978-83. https://pubmed.ncbi.nlm.nih.gov/1058782910 Abraham D, Rogers J, Gault P, Kushner JP, McClain DA. Increased insulin secretory capacity but decreased insulin sensitivity after correction of iron overload by phlebotomy in hereditary haemochromatosis. Diabetologia. 2006 Nov;49(11):2546-51. Epub 2006 Sep 22. https://pubmed.ncbi.nlm.nih.gov/17019598